The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Maintenance therapy with Xpovio may extend PFS in some endometrial cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In patients with wild-type TP53 advanced or recurrent endometrial cancer, the addition of maintenance therapy with Xpovio (selinexor) following systemic therapy may prolong progression-free survival, according to research that will be presented during the July 2023 session of the American Society of Clinical Oncology Plenary Series.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

EC approves Lynparza + Imfinzi for pMMR endometrial cancer

The European Commission approved Imfinzi (durvalumab) and Lynparza (olaparib) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient disease. Imfinzi plus chemotherapy followed by Imfinzi alone has been approved for patients with mismatch repair deficient disease.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account